ArticleNaunyn-Schmiedeberg's archives of pharmacology2026

FOXK2/SH2D3A axis recruits EGFR to drive papillary thyroid cancer progression and confers sensitivity to EGFR inhibition.

Qin Cui et al.PubMed ↗Publisher ↗

No numbers read from the abstract.